Marimed director awarded 75,000 RSUs

MARIMED INC. director Eva Selhub, M.D. reported a compensation-related equity award.

(Neutral)

(Neutral)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Form Type

Rhea-AI Filing Summary

MARIMED INC. director Eva Selhub, M.D. reported a compensation-related equity award. She received 75,000 Restricted Stock Units (RSUs), which are a form of stock-based compensation, at a grant price of $0.00 per unit.

According to the footnotes, these RSUs convert into common stock on a one-for-one basis and will vest in full one year from the grant date, based on the award agreement between the company and Selhub. The filing also shows she directly holds 482,671 shares of common stock following the reported transactions. This Form 4 reflects an equity grant rather than any open-market share purchase or sale.

Insider Trade Summary

Grant/Award: 75,000 shares

Grant/Award 2 txns

Insider Selhub Eva M.D.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Restricted Stock Units (RSU)	75,000	$0.00	$0.00
holding	Common stock	--	--	--

Holdings After Transaction: Restricted Stock Units (RSU) — 75,000 contracts (Direct); Common stock — 482,671 shares (Direct)

Footnotes (2)

F1. RSUs convert to shares of common stock on a one-for-one basis.
F2. The RSUs will vest in full one year from the date of grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person.

Key Figures

RSUs granted: 75,000 units Grant price per RSU: $0.00 per unit Underlying common shares: 75,000 shares +3 more

6 metrics

RSUs granted 75,000 units Equity grant to director Eva Selhub, M.D.

Grant price per RSU $0.00 per unit Restricted Stock Units grant on grant date

Underlying common shares 75,000 shares RSUs convert to common stock on a one-for-one basis

Common shares held 482,671 shares Total common stock held directly after transactions

RSU vesting period 1 year RSUs vest in full one year from grant date

Derivative transactions count 1 transaction One derivative-type RSU grant reported

Key Terms

Restricted Stock Units (RSU), grant, award, or other acquisition, convert to shares of common stock, vest in full one year from the date of grant

4 terms

Restricted Stock Units (RSU) financial

"security_title: "Restricted Stock Units (RSU)""

grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

convert to shares of common stock financial

"RSUs convert to shares of common stock on a one-for-one basis."

vest in full one year from the date of grant financial

"The RSUs will vest in full one year from the date of grant"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did MARIMED INC. (MRMD) report for Eva Selhub?

MARIMED INC. reported that director Eva Selhub, M.D. received 75,000 Restricted Stock Units (RSUs) as an equity grant. These RSUs are compensation-related and do not reflect an open-market share purchase or sale by the director.

How many RSUs did MARIMED INC. (MRMD) grant to director Eva Selhub?

MARIMED INC. granted director Eva Selhub, M.D. 75,000 Restricted Stock Units (RSUs). Each RSU represents the right to receive one share of common stock, providing stock-based compensation aligned with the company’s equity.

When do Eva Selhub’s 75,000 MARIMED (MRMD) RSUs vest?

The 75,000 RSUs granted to director Eva Selhub, M.D. will vest in full one year from the grant date. Vesting terms follow the award agreement between MARIMED INC. and the reporting person, as described in the Form 4 footnotes.

Do the MARIMED (MRMD) RSUs convert into common stock for Eva Selhub?

Yes. The Form 4 states that Eva Selhub’s RSUs convert to common stock on a one-for-one basis. Once vested and settled, each RSU will deliver one share of MARIMED INC. common stock to the reporting person.

How many MARIMED (MRMD) common shares does Eva Selhub hold after this filing?

Following the reported transactions, Eva Selhub, M.D. is shown holding 482,671 shares of MARIMED INC. common stock directly. This figure reflects her non-derivative share position as disclosed in the Form 4 filing.

Was there any open-market buying or selling of MARIMED (MRMD) shares by Eva Selhub?

No open-market buying or selling is indicated. The Form 4 shows a grant of 75,000 RSUs as compensation and a non-transactional line reflecting 482,671 common shares held, with no reported purchases or sales on the market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Accepted by SEC EDGAR 06/08/2026 - 04:19 PM EDT

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Selhub Eva M.D.

(Last)

(First)

(Middle)

C/O MARIMED INC.

10 OCEANA WAY

(Street)

NORWOOD

MASSACHUSETTS

02062

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
MARIMED INC. [ MRMD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/04/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common stock								482,671	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Restricted Stock Units (RSU)	⁽¹⁾	06/04/2026		A		75,000		⁽²⁾	⁽²⁾	Common Stock, par value $.001 per share	75,000	$0	75,000	D

Explanation of Responses:

1. RSUs convert to shares of common stock on a one-for-one basis.

2. The RSUs will vest in full one year from the date of grant in accordance with the terms of the award agreement between the Issuer and the Reporting Person.

Remarks:

The RSUs represent the annual equity grant under the Issuer's non-employee director compensation program.

	/s/ Eva Selhub	06/04/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR